Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS INC.
NASDAQ
$8.74
▼ DOWN 4.79% (-0.44)

KEY STATISTICS

Market Cap$700.14 M
52w High$14.87
52w Low$7.00
Dividend Yield—
Frequency—
P/E-4.35
Volume195.03K
Shares Out.80.11M

COMPANY

LEADERSHIP

Pedro J. Beltran
CHIEF EXECUTIVE
Pedro J. Beltran

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 12, 2025
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
88

PRICE TARGET

Target High$23.00
Target Low$23.00
Target Median$23.00
Target Consensus$23.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

PRICE

$8.74 ▼ DOWN 4.79% (−$0.44)
$8.70$8.85$9.00$9.159:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM8.74

About BridgeBio Oncology Therapeutics Inc.

https://bbotx.com ↗

BridgeBio Oncology Therapeutics, a clinical-stage biopharma focused on precision oncology targeting RAS and PI3Kα mutations, recently went public after raising $450M to advance its pipeline of small molecule therapies.

INDUSTRY

Biotechnology

A PRODUCT BRIDGEBIO ONCOLOGY THERAPEUTICS INC. IS KNOWN FOR

BBO-8520
BBO-8520

BBO-8520 is an investigational oral small molecule targeting KRASG12C, in Phase 1 trials for non-small cell lung cancer, with FDA Fast Track designation, and is BridgeBio Oncology's leading product candidate.

COMPETITORS

COMPETITOR
AMGN COMPARE
BMY COMPARE
LLY COMPARE
MRK COMPARE
RVMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
23
LISTED HERE
10
RANKED BY POSITION SIZE
VTI
0.00% · 1.4M
XBI
0.07% · 867.4K
IBB
0.03% · 321.4K
SCHA
0.01% · 225.3K
CANC
0.40% · 97.8K
BBC
0.71% · 40.5K
LABU
0.05% · 31.5K
SGRW
0.39% · 12.6K
CURE.AX
0.07% · 2.6K
VIRS
0.01% · 378

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.20%
HOLDERS
74
TOP 12 OF 74 · RANKED BY POSITION SIZE
Cormorant Asset Management, LP
17.9M sh · $160.01M
Deerfield Management Company, L.P. (Series C)
4.9M sh · $43.72M
Omega Fund Management, LLC
3.3M sh · $41.19M
Wellington Management Group Llp
2.9M sh · $36.4M
Alphabet Inc.
2.8M sh · $25.27M
Ecor1 Capital, LLC
2.8M sh · $25.27M
Enavate Sciences Gp, LLC
2.6M sh · $30.42M
Citadel Advisors LLC
2.5M sh · $31.68M
Paradigm Biocapital Advisors LP
2.3M sh · $28.32M
Novo Holdings A/S
2.2M sh · $19.56M
Blackrock, Inc.
2.1M sh · $18.69M
Laurion Capital Management LP
1.9M sh · $17.21M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Cobo Marc
Sale · 125 shares
2026-07-01
★
DIRECTOR, 10 PERCENT OWNER:
Chen Bihua
Purchase · 1.7M shares
2026-07-01
★
DIRECTOR, 10 PERCENT OWNER:
Chen Bihua
Purchase · 2.7M shares
2026-07-01
★
DIRECTOR, 10 PERCENT OWNER:
Chen Bihua
Purchase · 130.9K shares
2026-07-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
OVERWEIGHT 1
BUY 1
4 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT HC Wainwright & Co. BUY Wedbush OUTPERFORM Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
SEPN$38.91COMPARE
ANAB$56.28COMPARE
PHAT$9.18COMPARE